HD-OPM Archive

Know your numbers: targets for LDL, ApoB, Lp(a), BP, glucose and more

Which blood tests and measurements the group's posts treat as most informative for heart risk, and the targets quoted for each, from LDL and ApoB to Lp(a), blood pressure, HOMA-IR and HbA1c. It also covers which popular tests add little.

16 min read59 group posts cited37 studies discussed3 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • LDL-C goals scale with risk. The 2026 ACC/AHA guideline summarized in the group lists under 100 mg/dL for borderline or intermediate risk, under 70 for high risk and under 55 for very high-risk ASCVD.
  • ApoB counts atherogenic particles rather than their cholesterol. The group's quoted ideal is under 100 mg/dL, and under 80 for people at high risk.
  • Lp(a) is largely genetic and worth measuring at least once. The guideline flags 125 nmol/L (about 50 mg/dL) or higher, which carries roughly a 1.4-fold long-term risk of heart attack or stroke.
  • Systolic blood pressure under 120 mmHg is described as ideal, with drug-treatment targets under 130. SPRINT-based analyses cited projected 2.9 more years of survival from age 50 with the intensive target.
  • Insulin resistance shows up years before HbA1c rises. Quoted targets are HOMA-IR under 1.0 and HbA1c under 5.7%, and a creeping upward trend is a flag even inside the normal range.
  • Some tests add little: LDL particle size adds nothing once ApoB is known, circulating oxidized LDL does not predict risk after ApoB, and raising HDL with drugs has repeatedly failed.
In this summary
  1. The lipid numbers
  2. LDL targets by risk
  3. Lp(a): test once
  4. Blood pressure
  5. Blood sugar and insulin resistance
  6. Inflammation and imaging
  7. Reading numbers carefully
  8. What this means for you
  9. Frequently asked questions
  10. The evidence behind this summary

The short answer from the group's posts is that a handful of numbers do most of the work. For cholesterol, the group's admins favor ApoB (a count of plaque-forming particles) alongside LDL cholesterol and a one-time Lp(a). For blood pressure, they cite systolic readings under 120 mmHg as ideal. For metabolism, they look at HbA1c and, more sensitively, insulin-based measures such as HOMA-IR. Inflammation (hs-CRP) and a plaque imaging test round out the picture12.

Two caveats run through the posts. First, targets are not one-size-fits-all: LDL targets in particular scale with a person's absolute risk, and several posts warn against pushing very low values in people at low risk34. Second, many figures come from admin summaries of videos, guidelines and papers, so they are quoted here with attribution. The group's admins recommend discussing your own targets with your doctor.

1 in 5people are affected by high Lp(a), which needs testing only once2
2.9 yearsmore projected survival from age 50 with a systolic target under 120 rather than 140 (SPRINT)5
34%lower insulin sensitivity for 13 years before type 2 diabetes, while glucose and HbA1c looked normal6
35.9%of "low-risk" adults aged 40 to 65 already had coronary plaque7

The targets quoted in the posts, at a glance:

NumberQuoted targetSource
LDL-Cunder 100 mg/dL (borderline or intermediate risk), under 70 (high risk), under 55 (very high risk)2026 ACC/AHA guideline summary8
ApoBunder 100 mg/dL if healthy, under 80 at high riskGil Carvalho, summarized by Gokhan2
Lp(a)generally under 75 nmol/L; 125 nmol/L (50 mg/dL) or higher is flagged as highCarvalho; 2026 ACC/AHA guideline28
Triglyceridesunder 150 mg/dL (VLDL cholesterol under 30), likely lower at high riskLouis Nervegna9
Systolic blood pressureunder 120 mmHg ideal; drug-treatment target under 130Brad Stanfield, shared by Gokhan10
HOMA-IRunder 1.0 ideal; over 2.0 insulin resistance; over 3.0 frank resistanceCarvalho2
HbA1cunder 5.7%; a rise from 5.1 to 5.5 is a red flagCarvalho2

The lipid numbers

LDL-C: cholesterol carried in LDL particles

Your lab report's LDL-C measures the cholesterol inside LDL particles, and Louis Nervegna points out it also includes cholesterol carried by Lp(a) particles, so in someone with very high Lp(a) a significant share of reported LDL-C comes from Lp(a)1112. Genetics, Mendelian randomization and randomized trials support LDL and ApoB as causal risk factors rather than mere markers, according to an NEJM review Louis shared3.

ApoB: counting the particles

ApoB is a protein tag on every atherogenic particle (LDL, VLDL and Lp(a)), so an ApoB test counts the total number of those particles13. Louis explains that LDL-C and LDL-P (LDL particle number) can disagree: someone can have a low LDL-C but many small particles, and particle number predicts risk better than cholesterol content14. The group has shared an explainer on this "discordance"15, and a National Lipid Association consensus summary says ApoB is more accurate than LDL-C when the two diverge, particularly after statins, and is most useful for borderline-risk people deciding on a statin or those considering intensifying treatment, without being required for everyone16. A 2025 European Heart Journal paper concluded that lipid-related risk is best reflected by total ApoB particle count, largely independent of particle type or size, with elevated Lp(a) adding risk17.

Quoted targets: Gokhan Can's summary of Dr. Gil Carvalho gives ApoB ideally under 100 mg/dL for healthy people and under 80 for those at high risk2. The 2026 ACC/AHA guideline is quoted as saying ApoB may be used to assess residual risk and guide treatment, for example in people with cardiovascular-kidney-metabolic syndrome, type 2 diabetes, high triglycerides or known CVD who have already reached their LDL-C goals8.

You cannot compute ApoB from a standard panel, but non-HDL cholesterol (total minus HDL) is a rough proxy, and Louis shares a crude conversion of ApoB at about 0.7 times non-HDL-C, while stressing that a direct ApoB test is more accurate18. Mendelian randomization work Gokhan summarized found that genetically higher ApoB shortened healthspan, with an effect independent of LDL, and may raise Alzheimer's risk (the larger replication was attenuated)19.

Triglycerides and VLDL

Triglycerides are mostly carried by VLDL, an ApoB-tagged particle20. Louis estimates VLDL cholesterol as triglycerides divided by 5, with a normal VLDL below 30 mg/dL corresponding to triglycerides below 150 mg/dL, and says optimal is likely lower in high-risk people9. He also explains why triglycerides below 400 mg/dL are said not to matter in some discussions: they do matter, but they are already counted in ApoB, so adding them separately double counts risk21. In the BRIDGE-TIMI 73a trial, olezarsen cut triglycerides 64% with no change in plaque volume, and Louis argues that unless triglycerides exceed about 400-500 mg/dL, drug-lowering them makes little difference to plaque or hard outcomes22.

HDL: not a target to chase

Louis agrees with a post summarizing five major trials of HDL-raising drugs (niacin and CETP inhibitors) that failed to reduce events; in ILLUMINATE, for example, HDL rose 72% and cardiovascular death increased. He adds that risk falls only when HDL rises as a side effect of better insulin sensitivity, and that some HDL subfractions might still prove protective23.

Tests that add little

  • LDL particle size. An NMR report itself states that small LDL-P and size are associated with CVD risk, but not after LDL-P is taken into account, and ApoB is an equivalent particle count242526. Gokhan advises against paying for NMR size panels, citing a genetic analysis in about 200,000 people over 14 years in which ApoB and Lp(a) best captured lipid-driven risk27.
  • Oxidized LDL in blood. Louis says the association with CVD disappears or shrinks after adjusting for ApoB, because meaningful oxidation happens inside the artery wall, which no commercial test measures28.
  • Promotional explainers. One shared explainer claims ApoB, Lp(a), UACR and HbA1c reveal risks standard labs miss. It gives no studies and the claim that 20% of people carry Lp(a) risk is only asserted there29. Louis also shared a short explainer that standard panels do not capture Lp(a), remnants and ApoB-rich particles30.

LDL targets by risk

Several sources in the group agree on the broad structure.

  • 2026 ACC/AHA guideline (as summarized by Louis): under 100 mg/dL to prevent a first heart attack or stroke in borderline or intermediate risk, under 70 in high risk, and under 55 for people with ASCVD at very high risk8. A separate summary says explicit targets are back, and that a CAC score above 300 now triggers the highest-risk category with an LDL target under 5531.
  • ESC/EAS guideline (as shared by Louis): very high risk under 55 (under 40 in selected people with recurrent ASCVD), high risk under 70, moderate risk under 100 (consider), and low risk under 116 (may consider)3233.
  • 2023 JAHA review (summarized by Gokhan): high risk (10-year ASCVD risk of 20% or more) means at least a 50% LDL-C reduction and a goal under 70; very high risk means at least 50% reduction and under 55, or under 40 after recurrent events on statins. Statins are first-line, with ezetimibe, a PCSK9 inhibitor, bempedoic acid or inclisiran considered if the goal is not met34.
From the 2023 JAHA review Gokhan summarized: lifestyle across all stages, statins of rising intensity, and non-statin drugs (ezetimibe, PCSK9 inhibitors, bempedoic acid) as disease moves from no atherosclerosis to plaque progression to an event, with LDL-C goals of under 100, under 70 and under 55 mg/dL.
From the 2023 JAHA review Gokhan summarized: lifestyle across all stages, statins of rising intensity, and non-statin drugs (ezetimibe, PCSK9 inhibitors, bempedoic acid) as disease moves from no atherosclerosis to plaque progression to an event, with LDL-C goals of under 100, under 70 and under 55 mg/dL.34

Evidence for lower targets includes the EZ-PAVE randomized trial of over 3,000 people with established heart disease, in which an LDL goal under 55 (statin plus ezetimibe) had 6.6% major events over 3 years versus 9.7% with a goal under 70 (statin alone), with similar safety35. In imaging studies, Louis quotes an interview stating that at LDL near 80 mg/dL about half of people showed plaque regression, and below 60 about 90% of regressable lipid-rich plaques regressed36. A JACC Advances study of 1,033 asymptomatic adults aged 40-65 classified as low risk found 35.9% had coronary plaque, with atherosclerosis rising linearly with LDL, non-HDL and ApoB even below guideline levels; Gokhan reads it as supporting LDL under 707.

How low is too low?

The group does not treat "lower is better" as unlimited.

  • Gokhan notes expert opinion is shifting toward LDL under 30 as optimal, but this is not definitively proven in trials37.
  • Louis criticizes advice for low-risk people to use multiple drugs to push LDL-C under 20, noting major cardiology associations do not recommend it, and quotes Walter Willett on a possible increase in hemorrhagic stroke at very low LDL. He says this does not apply to high-risk people, for whom the benefit outweighs the risk, and that targets should scale with risk4.
  • An NEJM review he shared stresses proportionality, "not lower for everyone": focus on absolute risk, and use lifestyle rather than drugs in truly low-risk people3.
  • Louis also reminds readers that residual risk persists in every randomized trial however low LDL goes, and that age is the largest risk factor, by his estimate over 10 times larger than LDL or ApoB38.

Statin choice matters less than reaching the target: both atorvastatin 40-80 mg and rosuvastatin 20-40 mg typically cut LDL-C by 50% or more, and in the LODESTAR trial three-year outcomes did not differ significantly39.

Lp(a): test once

Lp(a) is a genetically determined lipoprotein. Carvalho's summary says it is about 90% genetic, does not change much with diet, affects about one in five people and generally should be under 75 nmol/L, and need only be tested once2. The 2026 ACC/AHA guideline, as quoted by Louis, says to measure it at least once in adulthood; 125 nmol/L or higher (50 mg/dL or higher) carries about a 1.4-fold higher long-term risk of heart attack or stroke, and 250 nmol/L at least two-fold8. A summary of the guideline update says universal screening is now recommended, matching Europe and Canada31.

Where risk begins is debated. A Mass General Brigham registry analysis suggested risk was already elevated from the 51st percentile (42-111 nmol/L, adjusted HR 1.14), above the median and well below the 125 nmol/L guideline cutoff (the 80th percentile)40. In the Women's Health Study, the top versus bottom fifth of Lp(a) had a hazard ratio of 1.33 for 30-year events41. In MESA, however, high Lp(a) raised risk only when hsCRP was 2 mg/L or higher (HR 1.36 for Lp(a) 50-99.9 mg/dL and 2.09 for 100 or more), in lower-risk people averaging age 6242. Louis's follow-up reading is that a CAC score under 100, hsCRP under 2 mg/L and low visceral fat seemed protective in MESA, though it is an observational cohort that cannot prove causality43.

Lp(a) risk starts rising well below the guideline cutoffMajor adverse cardiovascular events over more than a decade by Lp(a) percentile, Mass General Brigham registry, versus average or lower Lp(a)
interval clear of 195% confidence interval
51st–70th percentile (42–111 nmol/L)1.14 (1.05–1.24)
71st–90th percentile (112–215 nmol/L)1.21
The 125 nmol/L guideline cutoff is the 80th percentile. Risk leveled off above the 90th percentile. Source: 40
Show data
Adjusted hazard ratio95% CI
51st–70th percentile (42–111 nmol/L)1.141.05–1.24
71st–90th percentile (112–215 nmol/L)1.21–
MESA: cumulative incidence of cardiovascular disease by Lp(a) level. With hsCRP under 2 mg/L the three Lp(a) groups track together (log-rank P = 0.41); with hsCRP of 2 mg/L or more, Lp(a) of 100 mg/dL or more pulls clearly ahead (P = 0.001).
MESA: cumulative incidence of cardiovascular disease by Lp(a) level. With hsCRP under 2 mg/L the three Lp(a) groups track together (log-rank P = 0.41); with hsCRP of 2 mg/L or more, Lp(a) of 100 mg/dL or more pulls clearly ahead (P = 0.001).42

What to do about it: Louis shared Sam Tsimikas's reaction to the Lp(a)HORIZON trial of an Lp(a)-lowering drug, which Louis's post describes as having failed. Tsimikas does not see it as a failure. He suggests Lp(a) risk may instead be reduced by keeping LDL-C at or below 65, blood pressure at or below 120, other risk factors controlled and proven medicines taken, and describes treating his clinic patients with statins, ezetimibe and PCSK9 inhibitors44. A UK Biobank genetic analysis found the roughly 37% higher coronary risk from lifelong high Lp(a) was offset by lifetime LDL-C about 19 mg/dL lower, with larger reductions needed the later treatment starts45.

Blood pressure

Gokhan shares Dr. Brad Stanfield's explanation that systolic pressure under 120 mmHg is now seen as ideal, while drug treatment targets are under 130, since some people do not feel well at 12010. The same source cites SPRINT and a Chinese follow-up showing that targeting under 120 rather than 140 reduced heart attacks, strokes and death, with 25-27% lower mortality, while stressing individualized treatment in older adults to avoid dizziness and fainting46. A SPRINT follow-up estimated residual survival from age 50 at 37.3 versus 34.4 years (a 2.9-year difference), with fewer white matter lesions on the intensive arm; SPRINT enrolled people 50 or older with hypertension, without diabetes or prior stroke5. The video summaries also tie high pressure to dementia and recommend home monitoring, salt under 1,500 mg a day, a DASH diet, a potassium-rich diet, exercise, sleep and weight control, with medication when needed4647.

A lower blood pressure target added about 3 yearsEstimated residual survival at age 50 in a SPRINT follow-up analysis, by systolic blood pressure target
Intensive: target under 120 mmHg37.3 years
Standard: target under 140 mmHg34.4 years
Difference 2.9 years (95% CI 0.9–5.0). SPRINT enrolled people aged 50 or older with hypertension, without diabetes or prior stroke. Source: 5
Show data
Years of remaining life
Intensive: target under 120 mmHg37.3 years
Standard: target under 140 mmHg34.4 years

Hibiscus tea has small trial support for lowering pressure; Gokhan summarizes a 17-trial analysis showing a 7.1 mmHg drop in systolic pressure, though that is his blog's summary rather than a guideline48. Gokhan also reports, as an anecdote, a systolic reading of 107 after starting potassium10.

Blood sugar and insulin resistance

Carvalho's targets, as summarized by Gokhan, are HOMA-IR ideally under 1.0 (over 2.0 indicates insulin resistance and over 3.0 frank resistance) and HbA1c under 5.7%, noting even a rise from 5.1 to 5.5 is a red flag2. HOMA-IR is calculated from fasting glucose and fasting insulin2. Gokhan's own list of tracked targets includes BMI under 30, systolic pressure under 120, LDL under 70 and fasting glucose under 90 mg/dL, set with his physicians because of a chronic blood disorder, so these are personal rather than general49.

Why look beyond glucose and HbA1c? In the Whitehall II analysis Louis shared, people who developed type 2 diabetes had about 34% lower HOMA insulin sensitivity across the whole 13-year window, while glucose and A1C stayed in the normal range for years. The suggested earliest tests are fasting insulin and a 2-hour oral glucose tolerance test (OGTT) with insulin at 30, 60, 90 and 120 minutes6. Gokhan's lab list likewise includes fasting glucose, HbA1c, insulin and HOMA-IR1. Louis adds that an OGTT is the definitive test of whether diabetes has truly resolved, since a low A1C on a low-carb diet does not prove it50. He argues liver fat is the driver of insulin resistance and that continuous glucose monitors can mislead, citing his own A1C of 4.7 with liver fat under 1%, which is his position rather than a trial result51.

Infographic shared by Louis: fasting insulin and HOMA-IR rise first while glucose and HbA1c stay normal, and the standard panel only turns abnormal at the prediabetes stage.
Infographic shared by Louis: fasting insulin and HOMA-IR rise first while glucose and HbA1c stay normal, and the standard panel only turns abnormal at the prediabetes stage.6

Food can move these numbers. A meta-analysis of 102 feeding trials found polyunsaturated fat improved fasting glucose, HbA1c and HOMA-IR, monounsaturated fat did somewhat less, and saturated fat showed no appreciable benefit52. Psyllium lowered LDL by 13 mg/dL and ApoB by 5 mg/dL across 28 trials, and lowered HbA1c by 0.97% and fasting glucose by 37 mg/dL in people with type 2 diabetes, with little effect if blood sugar is normal53. A 74-trial analysis found oats lowered LDL-C by 0.29 mmol/L and fasting glucose by 0.25 mmol/L, although ApoB did not change significantly (only two studies)54. Taurine had modest effects in a meta-analysis (fasting glucose down 5.9 mg/dL, LDL down 6.5 mg/dL)55, and a 120-person trial found it lowered insulin and HOMA-IR in type 2 diabetes without changing HbA1c or lipids56.

Inflammation and imaging

hs-CRP predicts events independently of cholesterol, according to Gokhan's baseline lab list1. In the Women's Health Study, the top versus bottom fifth had a hazard ratio of 1.70 for hs-CRP, 1.36 for LDL and 1.33 for Lp(a), each independent, with the combination predicting best41. Gokhan's list also offers a CAC score or carotid ultrasound as the imaging option1. One keto practitioner's account shows why markers need watching on any diet: 15 years of keto lowered blood pressure, triglycerides, HbA1c, insulin and hsCRP but raised LDL and ApoB until ezetimibe was added57.

Inflammation, LDL and Lp(a) each added to 30-year riskWomen's Health Study: hazard ratio for 30-year cardiovascular events, top versus bottom fifth of each marker
hs-CRP1.70
LDL cholesterol1.36
Lp(a)1.33
Each marker contributed independently and the combination predicted best; observational data. Source: 41
Show data
Hazard ratio95% CI
hs-CRP1.70–
LDL cholesterol1.36–
Lp(a)1.33–

Reading numbers carefully

Observational U-shaped curves, where both low and high values look worse, appear for cholesterol, BMI, A1C and blood pressure alike. Louis explains these as reverse causality (illness itself lowers LDL, BMI, A1C or pressure), and notes randomized trials and Mendelian randomization show lower LDL causes lower risk5859. Lipid risk also depends on context: Louis says age matters most and many other risk factors remain after LDL is treated38.

What this means for you

  • A reasonable starting panel, per Gokhan: lipid panel, ApoB, Lp(a), hs-CRP, fasting glucose, HbA1c, insulin and HOMA-IR, with an imaging test, tracked over time in a spreadsheet1.
  • The group's admins recommend discussing LDL and ApoB goals with your doctor, using the risk-tiered targets above rather than a single number83234.
  • Test Lp(a) once; if it is high, the emphasis is on lowering LDL and controlling blood pressure and other risk factors844.
  • Home blood pressure monitoring is the first step in the video summaries the group shared46.
  • Skip tests with little added value, such as particle size and oxidized LDL, unless your doctor has a specific reason2428.

Frequently asked questions

Is ApoB better than LDL-C?

Per the posts, ApoB is more accurate when the two diverge, but the consensus does not require it for everyone1416.

What should my Lp(a) be?

Carvalho's summary says generally under 75 nmol/L2. The guideline flags 125 nmol/L or higher8, though one registry analysis suggested risk begins lower40.

Do I need to worry about my triglycerides?

Triglycerides below 400 mg/dL are already reflected in ApoB, and drug-lowering them alone did not shrink plaque2122.

Is an HbA1c in the normal range enough?

Not necessarily. HbA1c under 5.7% is the quoted target, but insulin resistance can precede abnormal HbA1c by years26.

Should I get my LDL as low as possible?

The group's view is that targets scale with risk: very low values are advised for high-risk people, not low-risk ones34.

The evidence behind this summary37 studies · 5 meta-analyses · 12 trials · 2 MR · 5 observational

The 59 group posts cited above discuss 37 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 5Randomized trials 12Mendelian randomization 2Observational studies 5Reviews & guidelines 8Other sources 5

Strongest evidence discussed

All 37 studies and sources
Sources from the group (59)
  1. Essential labs for heart disease prevention: lipids, hs-CRP, Lp(a), ApoB, glucose markers Gokhan Can · Aug 03, 2024 · Facebook
  2. Four blood tests for hidden metabolic and heart risk: HOMA-IR, A1C, Lp(a) and ApoB Gokhan Can · Jan 01, 2026 · Facebook
  3. NEJM review: LDL targets should scale with absolute risk, not 'lower for everyone' Louis Nervegna · Feb 05, 2026 · Facebook
  4. Louis: forcing LDL-C below 20 in low-risk people is unwise, per Willett on brain bleeds Louis Nervegna · Mar 30, 2024 · Facebook
  5. Intensive BP control in SPRINT: 2.9 more years of survival and less white matter damage Gokhan Can · Nov 17, 2023 · Facebook
  6. Insulin resistance precedes abnormal A1C by years; fasting insulin and OGTT catch it first Louis Nervegna · Jun 22, 2026 · Facebook
  7. Over a third of 'low-risk' adults had coronary plaque; low LDL and ApoB were protective Gokhan Can · Aug 18, 2024 · Facebook
  8. 2026 ACC/AHA lipid guideline keeps LDL targets and adds Lp(a), apoB and CAC testing Louis Nervegna · Mar 13, 2026 · Facebook
  9. VLDL cholesterol (triglycerides / 5) may be more atherogenic than LDL Louis Nervegna · May 02, 2024 · Facebook
  10. Video on how blood pressure targets evolved: ideal SBP under 120, drug targets under 130 Gokhan Can · Nov 22, 2025 · Facebook
  11. Lp(a) carries LDL cholesterol, so LDL-C on a lab report includes Lp(a) cholesterol Louis Nervegna · Jun 14, 2025 · Facebook
  12. Lp(a) carries LDL cholesterol, so lab LDL-C includes cholesterol from Lp(a) particles Louis Nervegna · Oct 10, 2025 · Facebook
  13. ApoB is the 'sign' on atherogenic particles; LDL and Lp(a) carry LDL cholesterol Louis Nervegna · Jun 15, 2025 · Facebook
  14. LDL-C vs LDL-P vs ApoB: particle number predicts risk better than cholesterol content Louis Nervegna · Jul 16, 2024 · Facebook
  15. Video: why ApoB is a better CVD risk marker than LDL-C and what discordance means Louis Nervegna · Mar 09, 2024 · Facebook
  16. NLA consensus clarifies when to measure ApoB and matching LDL-C thresholds Louis Nervegna · Dec 13, 2025 · Facebook
  17. Eur Heart J 2025: apoB particle count, not size or type, drives coronary risk Louis Nervegna · Apr 30, 2025 · Facebook
  18. ApoB cannot be calculated from a lipid panel but is roughly 0.7 times non-HDL cholesterol Louis Nervegna · Sep 02, 2025 · Facebook
  19. Mendelian randomization: higher ApoB shortens healthspan and may raise Alzheimer's risk Gokhan Can · Feb 25, 2024 · Facebook
  20. Lp(a) and triglycerides are ApoB particles, so accepting them but not LDL is odd Louis Nervegna · Jul 21, 2024 · Facebook
  21. Triglycerides still matter below 400 mg/dL but are already counted in ApoB Louis Nervegna · Feb 17, 2025 · Facebook
  22. Lowering triglycerides alone does not shrink plaque: olezarsen cut TG 64%, plaque flat Louis Nervegna · May 20, 2026 · Facebook
  23. Drugs that raise HDL have repeatedly failed to cut cardiovascular events Louis Nervegna · Jun 12, 2026 · Facebook
  24. LDL particle size does not predict CVD risk once particle number or ApoB is accounted for Louis Nervegna · Jan 22, 2025 · Facebook
  25. NMR reports state LDL particle size adds no risk information once LDL-P is accounted for Louis Nervegna · Jul 29, 2024 · Facebook
  26. NMR LDL particle size adds no risk information once LDL-P or ApoB is known Louis Nervegna · Apr 30, 2026 · Facebook
  27. ApoB and Lp(a) capture lipid risk; LDL particle size adds nothing once apoB is known Gokhan Can · May 02, 2025 · Facebook
  28. Circulating oxidized LDL tests do not predict CVD risk once ApoB is accounted for Louis Nervegna · Sep 12, 2024 · Facebook
  29. Why ApoB, Lp(a), UACR and HbA1c add to a standard cholesterol panel Louis Nervegna · Sep 25, 2026 · Facebook
  30. Standard cholesterol tests miss Lp(a), remnant and ApoB-rich particles Louis Nervegna · Dec 03, 2025 · Facebook
  31. 2026 ACC/AHA cholesterol guidelines bring back explicit LDL targets: under 55, 70 or 100 Louis Nervegna · May 01, 2026 · Facebook
  32. 2025 ESC/EAS LDL targets: below 55 mg/dL for very high risk, below 70 for high risk Louis Nervegna · Nov 20, 2025 · Facebook
  33. LDL targets by risk: below 55 for very high risk down to below 116 for low risk Louis Nervegna · May 21, 2025 · Facebook
  34. Evolving LDL-C management (JAHA 2023): risk categories, thresholds and treatment goals Gokhan Can · Nov 25, 2023 · Facebook
  35. EZ-PAVE: LDL target <55 vs <70 cut major CV events by 33% in over 3,000 patients Louis Nervegna · Mar 31, 2026 · Facebook
  36. Plaque regression is common when LDL falls to about 80 or below (Medscape interview) Louis Nervegna · Jun 14, 2025 · Facebook
  37. Expert opinion is shifting toward LDL below 30 mg/dL as optimal, but not proven in trials Gokhan Can · Oct 19, 2024 · Facebook
  38. Lowering LDL or ApoB is no cure: residual risk persists in every trial; age matters most Louis Nervegna · Aug 20, 2024 · Facebook
  39. Rosuvastatin lowers LDL slightly more than atorvastatin; LODESTAR outcomes were similar Louis Nervegna · Aug 14, 2026 · Facebook
  40. Lp(a) risk starts above the median, well below the 125 nmol/L guideline cutoff Louis Nervegna · May 09, 2024 · Facebook
  41. NEJM: hs-CRP, LDL and Lp(a) each predicted 30-year CVD risk in women, best combined Louis Nervegna · Aug 31, 2024 · Facebook
  42. MESA: high Lp(a) raised CVD risk only when hsCRP was 2 mg/L or higher Louis Nervegna · Jul 12, 2024 · Facebook
  43. MESA: CAC under 100, hsCRP under 2 and low visceral fat may protect those with high Lp(a) Louis Nervegna · Nov 10, 2026 · Facebook
  44. Tsimikas: Lp(a) risk can be managed with LDL under 65 and tight risk-factor control Louis Nervegna · Nov 10, 2026 · Facebook
  45. High Lp(a) risk offset by about 19 mg/dL lower lifelong LDL-C in UK Biobank analysis Louis Nervegna · Oct 23, 2025 · Facebook
  46. Dr Stanfield: systolic below 120 cut deaths 25-27% in SPRINT and a Chinese follow-up Gokhan Can · Sep 05, 2024 · Facebook
  47. Dr Brad Stanfield: 'normal' systolic BP near 140 raises dementia and CVD risk Gokhan Can · Feb 09, 2025 · Facebook
  48. Hibiscus tea raises nitric oxide markers and lowers blood pressure Gokhan Can · Dec 02, 2023 · Facebook
  49. One admin's story: high-risk blood disorder, LDL 70, hsCRP down from 1.2 to 0.2 Gokhan Can · Dec 05, 2023 · Facebook
  50. An oral glucose tolerance test is the definitive check that diabetes is truly resolved Louis Nervegna · Jul 31, 2025 · Facebook
  51. CGMs are a poor guide because liver fat drives insulin resistance Louis Nervegna · May 23, 2025 · Facebook
  52. 100+ trials: polyunsaturated fat improves glucose and insulin markers, saturated doesn't Louis Nervegna · Sep 14, 2025 · Facebook
  53. Psyllium lowers LDL 13 mg/dL and fasting glucose 37 mg/dL in type 2 diabetes Louis Nervegna · Jun 15, 2026 · Facebook
  54. 74 RCTs show oats lower LDL, blood sugar, weight and waist circumference Louis Nervegna · Jun 24, 2025 · Facebook
  55. Taurine lowered blood pressure, LDL, glucose and insulin resistance in a meta-analysis Louis Nervegna · May 20, 2026 · Facebook
  56. Taurine 3 g/day lowered insulin, HOMA-IR and inflammation in type 2 diabetes RCT Louis Nervegna · Jul 04, 2026 · Facebook
  57. Staying keto while still tracking ApoB and plaque markers (shared from Dominic D'Agostino) Gokhan Can · Aug 30, 2025 · Facebook
  58. U-shaped mortality curves for cholesterol, BMI, A1C and BP reflect reverse causality Louis Nervegna · Jun 12, 2024 · Facebook
  59. U-shaped mortality curves for cholesterol, BMI, A1C and BP reflect reverse causality Louis Nervegna · May 11, 2025 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary